Navigation Links
New and unique treatment for Psoriasis patients

Psoriasis patients who have been long-awaiting new options in treatment, now have fresh hope with the Food and Drug Administration's approval of the new drug, Amevive. This unique drug targets renegade immune cells to control hard-to-treat psoriasis. Psoriasis has been thought to occur when the immune system goes amok and cells called memory effector T cells prompt skin inflammation. The treatments that are currently available for psoriasis range from ointments to ultraviolet therapy to other injected drugs that can broadly suppress// the immune system. The new drug Amevive, however has been designed to target only the harmful T cells, instead of the entire immune system. Physicians have been eagerly awaiting the drug as it works differently from those drugs that are available in the market presently.

The drug, whose effect has not yet been compared with existing treatments, will be marketed in intravenous and intra-muscular injection forms. The treatment, for a 12-week course, will cost between $7000 and $10,000 and the weekly dose will be administered under the supervision of a doctor.

Biogen Inc., the makers of the drug, sponsored a study, which involved patients with chronic psoriasis that covered at least 10 percent of their bodies, and gave them either Amevive or dummy injections. They found that 40 per cent of patients on the Amevive drug saw their psoriasis symptoms cut in half, as compared to about 10 percent of placebo-treated patients. A small number of patients even saw their lesions almost vanish, for at least a while. Though the duration for which the effect lasted was not known, a small subset of patients went seven months or longer before needing additional treatment. The FDA's Dr. Karen Weiss cautioned that though the drug has a much more selective effect, it is still too soon to say it is very selective and very safe. In fact, she added that patients on the drug would require a blood test before each weekly dose to ensure the ir levels of infection-fighting immune cells have not dipped too low, which would require postponing a dose. Another theoretical concern is that by suppressing the immune system, the risk of cancer might increase. The FDA, while not restricting the number of times patients can repeat Amevive therapy when their psoriasis recurs, has warned that the effects of the drug on developing fetus is not yet known.


Related medicine news :

1. A unique factor in breathing disorder
2. Pink Shawl Project is a unique initiative
3. Thyroid hormone treatment hastens recovery after cardiac surgery
4. Feeding channel created by malaria parasite - a new target for malaria treatments
5. Now umbilical cord helps in stroke treatment.
6. Now AIDS treatment comes dirt-cheap
7. Breast cancer treatment to be determined by gene test
8. Hemopurifier may revolutionise AIDS treatment
9. New drug helps boost cancer treatment
10. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
11. Experimental treatment for Ebola Virus Shows promising results in mice
Post Your Comments:

(Date:11/27/2015)... VVA (PRWEB) , ... November 27, 2015 , ... ... motto of progress through sharing, the 2016 Building Better Radiology Marketing ... The conference will begin on Sunday, March 6, 2016, at Caesars Palace in ...
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... the largest, most successful and prominent nonprofit healthcare organizations in the country. They ... involvement with various organizations, and helped advance the healthcare industry as a whole ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ON (PRWEB) , ... November 26, 2015 , ... ... of a real-time eReferral system for diagnostic imaging in the Waterloo region. Using ... BMD and Nuclear Medicine tests directly from their electronic medical record (EMR) without ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... -- Lannett Company, Inc. (NYSE: LCI ) today ... Kremers Urban Pharmaceuticals Inc. (KU), the U.S. specialty ... S.A. (Euronext: UCB). --> ... UCB for total consideration of approximately US$1.23 billion, ... capital adjustment, a deduction of certain reimbursable amounts ...
(Date:11/26/2015)... 2015 Un nuevo enfoque combina ... el cáncer avanzado.   --> Un ... de Bremachlorin para el cáncer avanzado.   ... con la terapia fotodinámica de Bremachlorin para el cáncer ... --> Clinical Cancer Research . --> ...
(Date:11/26/2015)... 2015 --> --> ... to find optimal contrast weighting of MRI for patients ... signed a research agreement with SyntheticMR in order to use ... it is possible to generate multiple contrast images from a ... has left, thus making it possible to both fine tune ...
Breaking Medicine Technology: